SAN DIEGO, Aug. 04, 2026 (GLOBE NEWSWIRE) — iBio, I c. (NASDAQ: IBIO), a cli ical-stage biotech ology developi g lo g-acti g a tibody the apeutics fo obesity, ca diometabolic a d ca diopulmo a y diseases, today a ou ced the appoi tme t of Molly Ca , M.D., as Chief Medical Office , fu the st e gthe i g its executive leade ship as the compa y adva ces its cli ical-stage ca diometabolic pipeli e. A expe ie ced physicia with ove 30 yea s of cli ical, academic a d biopha maceutical expe ie ce i e doc i ology a d metabolic disease, D . Ca will lead the compa y’s global cli ical st ategy, medical affai s, a d egulato y i itiatives as it adva ces its pipeli e towa d late-stage developme t.
P io to joi i g iBio, D . Ca held se io cli ical developme t, medical affai s, busi ess developme t a d academic positio s at leadi g biopha maceutical compa ies a d i stitutio s, i cludi g Eli Lilly a d Compa y, GlaxoSmithKli e, CSL Beh i g, Wyeth, No thweste U ive sity a d the U ive sity of Washi gto . Most ece tly, she se ved as Cli ical Head a d Associate Vice P eside t of Lilly’s I suli a d Glucago F a chise, whe e she ove saw the compa y’s i suli po tfolio a d cli ical developme t team, i cludi g the Phase 3 p og am fo efsito a, a o ce-weekly i suli , as well as p og ams spa i g p a dial i suli , asal glucago , biosimila s a d legacy i suli s. D . Ca ea ed he M.D. f om Columbia U ive sity College of Physicia s a d Su geo s a d completed he eside cy a d fellowship i e doc i ology at the U ive sity of Washi gto .
“Addi g Molly to ou leade ship team is a c itical step as we adva ce ou obesity a d ca diometabolic pipeli e i to the cli ic,” said Ma ti B e e , D.V.M., Ph.D., Chief Executive Office a d Chief Scie tific Office of iBio. “He a e combi atio of deep scie tific expe tise i e doc i ology a d metabolic disease, togethe with ha ds-o expe ie ce leadi g cli ical p og ams ac oss all stages of developme t, will be i valuable as we adva ce IBIO-600 a d IBIO-610 i to thei ext cli ical phases. He appoi tme t eflects iBio’s g owth i to a cli ical-stage compa y a d st e gthe s ou ability to execute o ou p og ams with the igo a d focus equi ed to b i g them close to patie ts.”
“The scie ce behi d iBio’s cli ical ca didates is closely alig ed with my expe ie ce i e doc i ology, obesity, muscle biology a d ca diometabolic disease, a d I believe these p og ams have the pote tial to mea i gfully imp ove body compositio a d ove all quality of life fo patie ts,” added D . Ca . “I was also d aw to iBio’s clea cli ical visio , highly collabo ative cultu e, a d commitme t to t a slati g diffe e tiated scie ce i to ew medici es. I look fo wa d to wo ki g with this wo ld-class esea ch team to adva ce these ca didates th ough the cli ic.”
iBio also today a ou ced that the compa y has g a ted D . Ca optio s to pu chase 430,000 sha es of its commo stock as i duceme t awa ds outside the compa y’s 2023 Om ibus I ce tive Pla . The g a t was app oved by the Compe satio Committee a d made as a mate ial i duceme t to D . Ca ’s employme t i acco da ce with Nasdaq Listi g Rule 5635(c)(4).
The optio awa d has a exe cise p ice of $1.40 pe sha e, equal to the closi g p ice of the compa y’s commo stock o July 31, 2026, the g a t date, a d a te -yea te m. The optio will vest 25% o the o e-yea a ive sa y of the g a t date, with a additio al 6.25% vesti g eve y th ee mo ths the eafte , p ovided D . Ca emai s employed by the compa y th ough each applicable vesti g date. These i duceme t awa ds also p ovide fo accele ated vesti g i co ectio with a cha ge i co t ol of the compa y o ce tai i volu ta y te mi atio s of D . Ca ’s employme t.
Fo mo e i fo matio , visit www.ibioi c.com o follow us o Li kedI .
Ce tai stateme ts i this p ess elease co stitute “fo wa d-looki g stateme ts” withi the mea i g of the fede al secu ities laws. Wo ds such as “may,” “might,” “will,” “should,” “believe,” “expect,” “a ticipate,” “estimate,” “co ti ue,” “p edict,” “fo ecast,” “p oject,” “pla ,” “i te d” o simila exp essio s, o stateme ts ega di g i te t, belief, o cu e t expectatio s, a e fo wa d-looki g stateme ts. These fo wa d-looki g stateme ts a e based upo cu e t estimates a d assumptio s a d i clude stateme ts ega di g D . Ca leadi g the compa y’s global cli ical st ategy, medical affai s, a d egulato y i itiatives as it adva ces its pipeli e towa d late-stage developme t; the compa y adva ci g its obesity a d ca diometabolic pipeli e i to the cli ic; D . Ca ’s expe tise a d ha ds-o expe ie ce leadi g cli ical p og ams ac oss all stages of developme t bei g i valuable to the compa y as it adva ces IBIO-600 a d IBIO-610 i to thei ext cli ical phases; D . Ca ’s appoi tme t eflecti g iBio’s g owth i to a cli ical-stage compa y a d st e gthe i g the compa y’s ability to execute o its p og ams with the igo a d focus equi ed to b i g them close to patie ts; D . Ca ’s belief that these p og ams have the pote tial to mea i gfully imp ove body compositio a d ove all quality of life fo patie ts; iBio’s commitme t to t a slati g diffe e tiated scie ce i to ew medici es; the vesti g of the optio g a ted to D . Ca ; a d the accele ated vesti g of the i duceme t awa d i the eve t of te mi atio i co ectio with a cha ge i co t ol of the compa y o ce tai i volu ta y te mi atio s of D . Ca ’s employme t. While iBio believes these fo wa d-looki g stateme ts a e easo able, u due elia ce should ot be placed o a y such fo wa d-looki g stateme ts, which a e based o i fo matio available to us o the date of this elease. These fo wa d-looki g stateme ts a e subject to va ious isks a d u ce tai ties, ma y of which a e difficult to p edict that could cause actual esults to diffe mate ially f om cu e t expectatio s a d assumptio s f om those set fo th o implied by a y fo wa d-looki g stateme ts. Impo ta t facto s that could cause actual esults to diffe mate ially f om cu e t expectatio s i clude, amo g othe s, the co t ibutio s to be made by D . Ca ; iBio’s ability to obtai egulato y app ovals fo comme cializatio of its p oduct ca didates, o to comply with o goi g egulato y equi eme ts; egulato y limitatio s elati g to iBio’s ability to p omote o comme cialize its p oduct ca didates fo specific i dicatio s; accepta ce of iBio’s p oduct ca didates i the ma ketplace a d the successful developme t, ma keti g o sale of p oducts; whethe iBio will i cu u fo esee expe ses o liabilities o othe ma ket facto s; a d the othe facto s discussed i iBio’s fili gs with the SEC i cludi g its A ual Repo t o Fo m 10-K fo the yea e ded Ju e 30, 2025 a d its subseque t fili gs with the SEC o Fo ms 10-Q a d 8-K. The i fo matio i this elease is p ovided o ly as of the date of this elease, a d iBio u de takes o obligatio to update a y fo wa d-looki g stateme ts co tai ed i this elease o accou t of ew i fo matio , futu e eve ts, o othe wise, except as equi ed by law.
